Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Gary Romano, Adam L. Boxer, Megan J. Smithey, Lawrence Carter et al.
Citations
2 citations
Journal
Neurology
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
2.09
article
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005)
Gary Romano, Adam L. Boxer, Megan J. Smithey, Lawrence Carter, Leonardo Guizzetti, Bradley Boeve, Tiffany W. Chow, Giacomo Salvadore, Catherine J. Mummery, Barbara Borroni, Isabelle Le Ber, Julie Huang
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
NeurologyVol. 104(7_Supplement_1)
Institutions
Allen Institute for Brain Science (US), University of California, San Francisco (US), WinnMed (US), Alector (United States) (US), Institut du Cerveau (FR), University College London (GB), University of Brescia (IT)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN (P8-3.005) — Gary Romano, Adam L. Boxer, et al. · Neurology (2025) | TGRS Research Map | TGRS